Literature DB >> 9874475

Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis.

N Scolding1, R Franklin, S Stevens, C H Heldin, A Compston, J Newcombe.   

Abstract

In multiple sclerosis, partial remyelination is conspicuous in many lesions, but widespread and lasting myelin repair ultimately fails as disability and handicap accumulate. Thus far, the precise identity of the cell responsible for limited spontaneous myelin repair has remained obscure. In the rodent, the proliferative oligodendrocyte progenitor is the most efficient remyelinating cell; this has now been identified in cultures prepared from normal human brain, but has proved difficult to demonstrate in situ. We adapted techniques using antibodies against the human platelet-derived growth factor-alpha receptor to identify oligodendrocyte progenitors in human tissue sections. Small numbers of oligodendrocyte progenitors were found in normal adult human white matter. Progenitors were also demonstrable in acute and chronic lesions from patients dying with multiple sclerosis, but with no evidence of any marked reactive increase in cell numbers. Understanding the biology of the remyelinating cell, and in particular the reason for its apparent failure to repopulate demyelinated lesions, is important for the development of remyelination treatments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874475     DOI: 10.1093/brain/121.12.2221

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  82 in total

1.  Visualization of nonstructural changes in early white matter development on diffusion-weighted MR images: evidence supporting premyelination anisotropy.

Authors:  D Prayer; A J Barkovich; D A Kirschner; L M Prayer; T P Roberts; J Kucharczyk; M E Moseley
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

2.  Distinctive properties of human adult brain-derived myelin progenitor cells.

Authors:  Francesca Ruffini; Nathalie Arbour; Manon Blain; André Olivier; Jack P Antel
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 3.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 4.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

5.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

6.  Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice.

Authors:  Nathalie Picard-Riera; Laurence Decker; Cécile Delarasse; Karine Goude; Brahim Nait-Oumesmar; Roland Liblau; Danielle Pham-Dinh; Anne Baron-Van Evercooren
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

7.  Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells.

Authors:  Xiaoxin Cheng; Yaping Wang; Qian He; Mengsheng Qiu; Scott R Whittemore; Qilin Cao
Journal:  Stem Cells       Date:  2007-09-13       Impact factor: 6.277

Review 8.  Myelin repair strategies: a cellular view.

Authors:  Vittorio Gallo; Regina C Armstrong
Journal:  Curr Opin Neurol       Date:  2008-06       Impact factor: 5.710

9.  Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Yue Wang; Jaime Imitola; Stine Rasmussen; Kevin C O'Connor; Samia J Khoury
Journal:  Ann Neurol       Date:  2008-10       Impact factor: 10.422

Review 10.  Regulation of the timing of oligodendrocyte differentiation: mechanisms and perspectives.

Authors:  Hao Huang; Xiao-Feng Zhao; Kang Zheng; Mengsheng Qiu
Journal:  Neurosci Bull       Date:  2013-02-28       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.